Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: malignancy at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · subfertile women with PCOS
It is very uncertain whether chinese herbal medicine (CHM) plus follicle aspiration plus… changes multiple pregnancy (adverse events) compared with follicle aspiration plus ovulation induction (very low certainty).
1 finding from 1 review
Serious adverse events Not reported · Patients with shoulder pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse outcome: total events · adults with fractures of the patella
It is very uncertain whether percutaneous patellar osteosynthesis changes major adverse outcome: total events compared with open surgery (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with oxycodone (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
MST vs ECT ‐ serious adverse events · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: haemorrhagic stroke · healthy people
Vitamin E leads to higher adverse events: haemorrhagic stroke compared with placebo (high certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Number of women with adverse events · pelvic organ prolapse in women
Any pessary may leads to higher number of women with adverse events compared with pelvic floor muscle training (PFMT) (low certainty).
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children with SMA type II
Intrathecal injected nusinersen showed no clear difference in adverse events related to treatment compared with sham procedure (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III
Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
Subcutaneous somatotropin showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
RR 1.57 [0.78, 3.17]
19 participants
Low
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low